DRUG
Linaclotide
Oral capsule
Status
Completed
Phase
Phase 3
Enrollment
614
Locations
79
Results
Posted
Publications
2
Study summary
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
This study consists of a 12-week Treatment Period followed by 4-week Randomized Withdrawal (RW) Period.
Interventions
DRUG
Oral capsule
DRUG
Matching placebo oral capsule
Timeline
First posted
Jun 29, 2018
Study start
Jun 20, 2018
Primary completion
Mar 13, 2019
Study completion
Apr 10, 2019
Results posted
Nov 16, 2020
Registry updated
Dec 1, 2020
Outcomes
Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period
Time frame · Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)
A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). Baseline abdominal score was derived from the eDiary data collected daily in the Pretreatment Period, specifically the period of time from 14 days before randomization up to the time of randomization. The participant's abdominal score was averaged on a weekly basis, and each weekly change from baseline was calculated for the treatment period and used as the dependent variable in the mixed model with repeated measures (MMRM) model. MMRM results are based on a model with treatment, analysis week, region and treatment-by-week interaction as fixed effects and baseline as a covariate. An unstructured covariance structure was used to model intra-subject correlation with subjects as a random effect.
Cumulative Distribution of Change From Baseline in 12-Week Abdominal Score
Time frame · Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)
A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). Baseline abdominal score was derived from the eDiary data collected daily in the Pretreatment Period, specifically the period of time from 14 days before randomization up to the time of randomization. The 12-week abdominal score was the average of the non-missing abdominal scores reported over the course of the treatment period. Change from baseline (BL) was calculated as the 12-week score minus the baseline score. The table presents the percentage of participants whose 12-week change from baseline was less than or equal to the threshold value of the score change (cumulative distribution of change).
Percentage of 6/12 Week Abdominal Score Responders (Responder Rate)
Time frame · Baseline (14 days before randomization up to the time of randomization), Treatment Period (Weeks 1-12)
A 6/12 week abdominal score responder is a participant who meets the weekly abdominal score responder criteria for at least 6 out of the 12 weeks of the Treatment Period. For each week in the Treatment Period, a weekly abdominal score responder is a participant who has an improvement from baseline of at least 2 points (ie, a -2 point change from baseline) in the respective weekly abdominal score. If a participant did not have at least 4 completed eDiary entries for a particular Treatment Period week, the participant was not considered a responder for that week. A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). The participant's abdominal score was averaged on a weekly basis, and each weekly change from baseline was calculated for the treatment period.
Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Over Time in the Treatment Period
Time frame · Baseline (14 days before randomization up to the time of randomization), Weeks 1-12
A participant's daily abdominal score was calculated as the average of daily e-diary abdominal pain, abdominal bloating and abdominal discomfort scores, each based on an 11-point scale of 0 (none) and 10 (worst possible). Baseline abdominal score was derived from the eDiary data collected daily in the Pretreatment Period, specifically the period of time from 14 days before randomization up to the time of randomization. The participant's abdominal score was averaged on a weekly basis, and each weekly change from baseline was calculated for the treatment period and used as the dependent variable in the mixed model with repeated measures (MMRM) model. MMRM results are based on a model with treatment, analysis week, region and treatment-by-week interaction as fixed effects and baseline as a covariate. An unstructured covariance structure was used to model intra-subject correlation with subjects as a random effect.
Eligibility
Inclusion Criteria: * Patient has no clinically significant findings on a physical examination and clinical laboratory tests * Female patients of childbearing potential must agree to use one of the following methods of birth control: 1. Hormonal contraception 2. Double-barrier birth control 3. Maintenance of a monogamous relationship with a male partner who has been surgically sterilized by vasectomy * Patient meets protocol criteria for diagnosis of IBS-C * Patient demonstrates continued IBS-C symptoms through Pretreatment Period * Patient maintains a minimum level of compliance with daily diary Exclusion Criteria: * Patient has history of loose or watery stools * Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain * Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility * Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Clinical Research Associates
Huntsville, Alabama, United States
Elite Clinical Studies
Phoenix, Arizona, United States
Adobe Clinical Research, LLC
Tucson, Arizona, United States
Arkansas Gastroenterology
North Little Rock, Arkansas, United States
GW Research, Inc.
Chula Vista, California, United States
Kindred Medical Institute for Clinical Trials, LLC
Corona, California, United States
Diagnamics, Inc.
Encinitas, California, United States
MD Studies, Inc.
Fountain Valley, California, United States
Paragon Rx Clinical, Inc. - Garden Grove
Garden Grove, California, United States
Grossmont Center For Clinical Research
La Mesa, California, United States
Facey Medical Foundation
Mission Hills, California, United States
Providence Clinical Research
North Hollywood, California, United States
Precision Research Institute
San Diego, California, United States
Paragon Rx Clinical, Inc.- Santa Ana
Santa Ana, California, United States
Millennium Clinical Trials
Thousand Oaks, California, United States
St. Joseph Heritage Healthcare
Yorba Linda, California, United States
Connecticut Clinical Research Institute
Bristol, Connecticut, United States
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Clinical Research of South Florida
Coral Gables, Florida, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
Palmetto Research, LLC
Hialeah, Florida, United States
Nature Coast Clinical Research, LLC
Inverness, Florida, United States
The Chappel Group Research
Kissimmee, Florida, United States
Jesscan Medical Research
Miami, Florida, United States
Publications
Related trials
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.